Although conventional combination chemotherapy produces responses in 40-70% of women with advanced breast cancer and prolongs survival in certain groups in the adjuvant setting, overall the results of cytotoxic treatment for breast cancer remain poor. The potential benefits of dose intensification have been extensively discussed (Hryniuk et al., 1984; Henderson et al., 1988) . The observation of durable complete responses following high-dose chemotherapy with autologous bone marrow or peripheral blood progenitor cell support is persuasive and encouraging (Eddy, 1992) . The results of randomised trials comparing high-dose and conventional adjuvant chemotherapy in women with poor-prognosis breast cancer are awaited with interest, and should clarify the benefits (and costs) of such intensive therapy. However, it is clear that high-dose chemotherapy is not appropriate for all women with breast cancer who require adjuvant chemotherapy. An alternative strategy is dose intensiiation of established chemotherapy combinations with haematopoietic growth factor support. Several trials have shown that granulocyte colony-stimulating factor (G-CSP) and granulocytemacrophage colony-stimulating factor (GM-CSF) can ameliorate or prevent chemotherapy-induced neutropenia (Bronchud et Groopman et al., 1989) . In addition, for chemotherapeutic regimens whose dose-limiting toxicity is neutropenia, these growth factors can facilitate delivery of conventional or higher doses of cytotoxic at shortened intervals. Thus combinations of doxorubicin and cyclophosphamide (Bronchud et al., 1989) , 5-fluorouracil, doxorubicin and cyclophosphamide (van Hoef et al., 1994) and 5-fluorouracil, epirubicin and cyclophosphamide (Ard1izoni et al., 1994) have been successfully delivered at 2 week intervals with growth factor support in women with advanced breast cancer. However, other studies have found that such doseintensive regimens produce excessive toxicity (Ferguson et al., 1993; Osborne et al., 1994) , and the increase in dose intensity has been limited to about 30%.
In this phase I study we have explored the dose intensification of the combination of 5-fluorouracil, epirubicin and cyclophosphamide given to women with breast cancer at 2 week intervals with haemopoietic support from lenograstim (G-CSF). Although grade 4 neutropenia was frequent at both dose levels, this was short-lived, and in all patients who received G-CSF the neutrophil count had recovered by the first day of the next course of chemotherapy (median day 15 neutrophil count 32.5 x 10' 1', range 6.4-98). Severe neutropenia (<0.1 x 109 1'-l) occurred in two patients at level A and four patients at level B. There was no evidence of cumulative neutropenia during the course of treatment, and indeed the day 8 neutrophil count tended to rise with continuing chemotherapy (Table IV) . In contrast thrombocytopenia and anaemia progressively worsened during the course of chemotherapy (Figure 1 ). Although no patient required platelet transfusion, packed red cell transfusions were administered to five out of six patients at level A and five out of eight at level B; the median number of units transfused was 4 (range 2-7). Only one patient at level B developed neutropenic sepsis requiring intravenous antibiotics. A second patient at this dose presented with fever and bilateral pulmonary infiltrates in the presence of a normal neutrophil count 10 days after the fourth course of chemotherapy. This patient had no known metastatic disease. Despite intravenous broadspectrum antibiotics her condition deteriorated with worsening hypoxia and radiological evidence of progressive pneumonia. Although bronchial washings were negative, a presumptive diagnosis of Pnewnocystis pneumonia was made, and following treatment with high-dose cotrnmoxazole she mad a complete recovery. In the light of this unexpected toxicity, the fall in lymphocyte count was examined for each treatment course. Transient grade 4 lymphopenia occurred in three patients (nine courses) at level A and in all eight patients (22 courses) at level B, and there was evidence of cumulative toxicity with continuing chemotherapy.
The other chemotherapy-related toxicities including nausea and vomiting, mucositis, diarrhoea and aesthenia were manageable and predictable. Reversible alopecia was universal. One patient had an episode of paroxysmal supraventricular tachycardia after the fifth course of chemotherapy at level A. She was withdrawn from the study but subsequently had a normal echocardiogram and 24h electrocardiogram. No other cardiac toxicity was recorded in the study.
In general the G-CSF injections were well tolerated. Four patients had bone pain or 'flu-like' symptoms, and 11 had elevation of alkaline phosphatase attributable to G-CSF (seven grade 1, four grade 2).
Dose intensity analysis
The 'conventional' regimen, 5-fluorouracil 600 mg m epirubicin 60 mg m-2, and cyclophosphamide 600 mg kg-2 administered at 3 week intervals for six courses, was arbitrarily assigned a relative dose intensity of 1.0. The median dose intensity with FEC level A was 360mgm-2week-' 5-fluorouracil and cyclophosphamide and 36 mg m-2 week-' epirubicin, equivalent to a relative dose intensity of 1.5. For the four patients who completed treatment at level B, the relative dose intensity achieved was 1.75. Although haematopoietic growth factors are certainly effective in ameliorating neutropema after chemotherapy, the optimum timing and duration of their administration is uncertain. The day 15 counts recorded in this study suggest that G-CSF could safely be withdrawn before day 14, and other studies have been able to achieve similar acceleration of chemotherapy with growth factors administered only from days 2 to 11 or days 2 to 8 of each course (Lichtman et al., 1993; van Hoef et al.. 1994) . Cumulative haematological toxicities were dose limiting in our study. Although in the future it is likely that thrombocytopenia may be abrogated by the use of another cytokine, in the light of our observation of cumulative lymphopenia and a presumed case of Pneumocstis pneumonia we would suggest that future studies of accelerated chemotherapy should monitor alterations in the circulating lymphocyte populations.
This approach to dose intensification is manageable in the out-patient clinic and may be most appropriate to the adjuvant setting, where modest increments in cytotoxic doses may result in inproved survival (Wood et al., 1994) . Further studies are required to compare the efficacy of this regimen with conventional chemotherapy.
